Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin

Gastroenterology

Volumn 131, Issue 4, 2006, Pages 1040-1048

  Bronowicki, Jean Pierre ^a   Ouzan, Denis ^b   Asselah, Tarik ^c   Desmorat, Hervé ^d   Zarski, Jean Pierre ^e   Foucher, Juliette ^f   Bourlière, Marc ^g   Renou, Christophe ^h   Tran, Albert ⁱ   Melin, Pascal ^j   Hézode, Christophe ^k   Chevalier, Michelle ^k   Bouvier Alias, Magali ^l   Chevaliez, Stéphane ^l   Montestruc, François ^m   Lonjon Domanec, Isabelle ^m   Pawlotsky, Jean Michel ^l  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSTITUT ARNAULT TZANCK   (France)

^c BEAUJON HOSPITAL   (France)

^d Clinique du Parc   (France)

^e HÔPITAL MICHALLON   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g HÔPITAL SAINT JOSEPH   (France)

^h Hôpital d'Hyères   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j Department of Hepatology and Gastroenterology   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l Laboratoire Mérieux   (France)

^m Roche Laboratories   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS LOAD;

EID: 33749360440     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.07.022     Document Type: Article

References (29)

1. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36 (2002) S3-S20
2. Pawlotsky J.M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59 (2003) 1-11
3. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
4. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
5. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
7. Pawlotsky J.M., Dahari H., Neumann A.U., Hezode C., Germanidis G., Lonjon I., Castera L., and Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126 (2004) 703-714
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr. H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., and Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) S237-S244
10. Afdhal N.H. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 33 (2004) S25-S35
11. Gourlain K., Soulier A., Pellegrin B., Bouvier-Alias M., Hezode C., Darthuy F., Remire J., and Pawlotsky J.M. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J Clin Microbiol 43 (2005) 1669-1673
12. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
13. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Chaneac M., and Reddy K.R. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 425-433
14. Morice Y., Roulot D., Grando V., Stirnemann J., Gault E., Jeantils V., Bentata M., Jarrousse B., Lortholary O., Pallier C., and Deny P. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 82 (2001) 1001-1012
15. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., and Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005) 962-973
16. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., Morishima C., Wright E.C., Everson G.T., Lok A.S., Morgan T.R., Bonkovsky H.L., Lee W.M., Dienstag J.L., Ghany M.G., Goodman Z.D., and Everhart J.E. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
17. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
18. Guo J.T., Bichko V.V., and Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 75 (2001) 8516-8523
19. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., Dhumeaux D., Maurel P., and Pawlotsky J.M. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 76 (2002) 8189-8199
20. Lau J.Y., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
21. Neumann A.U., Zeuzem S., Ferrari C., Lurie Y., Negro F., Germanidis G., Esteban J., Hellstrand K., Pellegrin B., Soulier A., Haagmans B., Abrignani S., Colucci G., Schalm S., and Pawlotsky J.M. Ditto-HCV early viral kinetics report. Novel decline patterns in genotype 1 but not genotypes 2-3 patients treated with peginterferon alfa-2a and ribavirin. J Hepatol 36 Suppl 1 (2002) 121
22. Herrmann E., Lee J.H., Marinos G., Modi M., and Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37 (2003) 1351-1358
23. Hultgren C., Milich D.R., Weiland O., and Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 79 (1998) 2381-2391
24. Dixit N.M., Layden-Almer J.E., Layden T.J., and Perelson A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432 (2004) 922-924
25. Pawlotsky J.M. How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection?. J Hepatol 42 (2005) 951-953
26. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76 (2002) 8505-8517
27. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98 (2001) 6895-6900
28. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6 (2000) 1375-1379
29. Chevaliez S., Brillet R., Hezode C., Dhumeaux D., and Pawlotsky J.M. Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus RNA load upon therapy. Hepatology 42 Suppl 1 (2005) 679A